The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Treatment efficacy implications of incorrect utilization of tumor marker levels and risk group assignment according to the International Germ Cell Consensus Classification (IGCCCG).
 
Tim Nestler
Consulting or Advisory Role - Janssen Oncology; Novartis
Speakers' Bureau - Janssen Oncology
 
Pia Paffenholz
Honoraria - BMS GmbH & Co. KG; Eisai; Janssen; Merck
Consulting or Advisory Role - Janssen; Merck; Roche
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Ipsen; Janssen; Medac; Merck
 
Christian Ruf
No Relationships to Disclose
 
Yue Che
No Relationships to Disclose
 
Christoph Alexander Seidel
No Relationships to Disclose
 
Julia Heinzelbecker
No Relationships to Disclose
 
Hans Schmelz
No Relationships to Disclose
 
Cord Matthies
No Relationships to Disclose
 
Peter Albers
No Relationships to Disclose
 
Carsten Bokemeyer
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb; Hexal; I-Med Institute; Medac; Medupdate; Merck KGaA; Merck Sharp Dohme; Roche; Sanofi
Consulting or Advisory Role - AOK Health Insurance; Bayer Schering Pharma; BioNTech SE; Janssen-Cilag GmbH; Lindis Biotech; Merck Sharp & Dohme; Oncology Drug Consult (ODC); Sanofi
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); Agile Therapeutics (Inst); Alexion Pharmaceuticals (Inst); Amgen (Inst); Apellis Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BerGenBio (Inst); BioNTech SE (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); CPT Cellex Patient Treatment (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Glycostem (Inst); Glycotope GmbH (Inst); immatics (Inst); Incyte (Inst); IO Biotech (Inst); Ipsen (Inst); Isofol Medical (Inst); Janssen-Cilag (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Millennium (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Rafael Pharmaceuticals (Inst); Roche (Inst); Servier/Pfizer (Inst); Springworks Therapeutics (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Janssen-Cilag; Merck Serono; Sanofi
 
Axel Heidenreich
Honoraria - Amgen; Astellas Pharma; Bayer; Ferring; Ipsen; Janssen-Cilag; Sanofi; Takeda
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; BMS Global; Clovis Oncology; Janssen-Cilag; MSD Oncology
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Ipsen; Johnson & Johnson; Pfizer; Sanofi; Takeda
Research Funding - Astellas Pharma; Bayer; BMS Oncology; Sanofi
 
Martin Pichler
No Relationships to Disclose
 
Matthaeus Majewski
No Relationships to Disclose